Comparative Pharmacology
Head-to-head clinical analysis: MYTREX A versus SULTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYTREX A versus SULTRIN.
MYTREX A vs SULTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate inhibits dihydrofolate reductase, leading to depletion of tetrahydrofolate and inhibition of DNA synthesis and cell proliferation. Also has immunomodulatory effects via adenosine release.
Sultrin (sulfanilamide, sulfathiazole, sulfacetamide) is a triple sulfonamide combination that acts as a bacteriostatic agent. It inhibits bacterial folic acid synthesis by competing with para-aminobenzoic acid (PABA) for the active site of dihydropteroate synthase, thereby blocking the conversion of PABA to dihydrofolic acid. This disrupts nucleic acid synthesis in susceptible bacteria.
Methotrexate (MYTREX A) 7.5-25 mg orally once weekly, or 15-25 mg intramuscularly/subcutaneously once weekly for rheumatoid arthritis; in oncology, dosing varies per protocol.
Intravaginal administration: one applicatorful (approximately 5 g) of Sultrin Triple Sulfa Cream (containing sulfathiazole, sulfacetamide, and sulfabenzamide) intravaginally once or twice daily for 4 to 7 days. Oral: Not applicable.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in normal renal function; prolonged to 24-30 hours in moderate to severe renal impairment (CrCl <30 mL/min).
Terminal half-life 8-12 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min)
Renal: 90% unchanged drug; fecal: <10% via bile; minor hepatic metabolism to inactive metabolites.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic